Latest stories on CYTK
Cytokinetics to Announce Third Quarter Results on November 4, 2026
Business Insider50 · neutralearnings
Cytokinetics to Announce Third Quarter Results on November 4, 2026
GlobeNewswire50 · neutralearnings
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire50 · neutralgeneral
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Insider50 · neutralgeneral
Cytokinetics announces Health Canada approval of Myqorzo for oHCM treatment
The Fly74 · bullishproduct/pr
Cytokinetics initiated with an Outperform at William Blair
The Fly63 · neutralanalyst
William Blair initiates Cytokinetics stock coverage with outperform rating
Investing.com Analyst Ratings63 · neutralanalyst
UBS cuts Cytokinetics stock price target on valuation, keeps Buy
Investing.com Analyst Ratings52 · neutralanalyst
Cytokinetics price target lowered to $104 from $115 at UBS
The Fly34 · bearishanalyst
Cytokinetics announces additional data from ACACIA-HCM trial at HFSA
The Fly61 · neutralproduct/pr
Cytokinetics Announces Additional Data from ACACIA-HCM Presented at the HFSA Annual Scientific Meeting 2026
Business Insider61 · neutralproduct/pr
Cytokinetics Announces Additional Data from ACACIA-HCM Presented at the HFSA Annual Scientific Meeting 2026
GlobeNewswire61 · neutralproduct/pr
Cytokinetics price target raised to $113 from $112 at RBC Capital
The Fly56 · neutralanalyst
Cytokinetics Announces Four Upcoming Presentations at the HFSA Annual Scientific Meeting 2026
GlobeNewswire55 · neutralproduct/pr
Cytokinetics Announces Four Upcoming Presentations at the HFSA Annual Scientific Meeting 2026
Business Insider56 · neutralproduct/pr
Cytokinetics announces start of ASPEN-HCM
The Fly56 · neutralproduct/pr
Cytokinetics Launches ASPEN-HCM: A Real-World Study Evaluating MYQORZO® (aficamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy
GlobeNewswire56 · neutralproduct/pr
Cytokinetics Launches ASPEN-HCM: A Real-World Study Evaluating MYQORZO® (aficamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy
Business Insider56 · neutralproduct/pr
Cytokinetics (CYTK): Can Myqorzo Growth Create a New Biopharma Success Story?
Yahoo Top56 · neutralgeneral
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Insider50 · neutralgeneral
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire50 · neutralgeneral
Cytokinetics, Incorporated (CYTK) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Seeking Alpha56 · neutralgeneral
Cytokinetics: Why Myqorzo Doesn't Make Me A Buyer Yet
Seeking Alpha42 · neutralproduct/pr
Cytokinetics Announces Call for Proposals for Ninth Annual Communications Grant Program
Business Insider50 · neutralgeneral